The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

APR-246 plus azacitidine for patients with TP53 mutated MDS and AML

Jul 30, 2020
Share:

Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) harboring TP53 mutations have poor prognosis. Response to treatment is generally short, and the risk of relapse following allogeneic stem cell transplantation (allo-SCT) is heightened in this subset of patients.

APR-246 reactivates mutant p53 via a number of mechanisms and has exhibited synergy with azacitidine (AZA) both in-vitro and in-vivo. Preclinical data have provided the rationale for clinical evaluation of the combination, and a phase II study conducted by the Groupe Francophone des Myélodysplasies (GFM) is currently underway. The GFM-APR trial (NCT03931291) is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant AML or MDS following allo-SCT. Results were presented at this year’s virtual European Hematology Association (EHA) Annual Congress by Thomas Cluzeau.

Study design

  • A total of 53 adult patients with TP35 mutated MDS (intermediate, high, and very high revised International Staging System [ISS-R] scores) or AML (including > 30% bone marrow blasts) were enrolled between September 2018 and July 2019 across seven GFM centers
  • All patients were intended to receive six sessions of the following treatment regimen in 28-day cycles:
    • APR-246 4,500 mg intravenous (IV)/day (6-hour infusions; days 1–4)
    • AZA 75 mg/m²/day (days 4–10)
  • Allo-SCT was advised following 3–6 treatment cycles, followed by maintenance treatment with
    • APR-246 3,700 mg IV/day (6-hour infusions; days 1–4)
    • AZA 36 mg/m²/day (days 1–5)

Endpoints

  • Primary endpoint: Response of intention to treat and all evaluable patients* determined using the International Working Group (IWG) 2006 and 2003 criteria for MDS and AML, respectively
  • Secondary endpoints: Safety, overall survival (OS), duration of response (DoR), AML disease progression, and correlation of TP53 variant allele frequency with p53 expression

*Patients who received ≥ 3 cycles and underwent bone marrow (BM) evaluation

Results

  • A total of 52 patients were enrolled by July 2019 (Table 1)
  • Data cutoff: April 1, 2020

Table 1. Baseline patient characteristics

AML, acute myeloid leukemia; IPSS-R, revised International Prognostic Scoring System; MDS, myelodysplastic syndromes, WHO, World Health Organization

Total patients (N = 52)

MDS (% of patients) (n = 34)

AML (% of patients) (n = 18)

Median age, years (range)

74 (46–87)

72 (44–83)

Male/Female

15/19

12/6

WHO 2016 classification, %

 

 

MDS IPSS-R

 

 

   Intermediate

12

   High

15

   Very high

74

AML

 

 

   20–30% blasts

61

   > 30% blasts

39

Cytogenetic risk, %

 

 

Complex karyotype

85

89

Monosomal karyotype

79

50

del(5q)

53

67

Efficacy

  • Overall response rates (ORRs) in patients who received APR-246 + AZA are shown in Figure 1
    • ORR in all evaluable patients (BM evaluated after at least three cycles) according to the WHO classification was 75% in MDS, 78% in AML < 30 blasts, 100% AML > 30 blasts
  • OS rates were superior in patients who received ≥ 3 cycles of APR-246 + AZA (Table 2)
    • Median follow-up was 9.7 months

Figure 1. ORRs at A varying analysis timepoints and B according to WHO disease classification


CR, complete response; CRi, CR with incomplete count recovery; HI, hematologic improvement; PR, partial response; SD, stable disease; WHO, World Health Organization

Table 2. Patient OS rates

AML, acute myeloid leukemia; ITT, intention to treat; MDS, myelodysplastic syndrome; OS, overall survival

OS

Median OS, months

95% CI

P

ITT cohort

12.1

8.9–15.3

 

Disease

 

 

0.34

MDS

12.1

8.9–15.3

 

AML 20–30% blasts

13.9

5.4–22.5

 

AML > 30% blasts

3.0

0.0–6.5

 

Treatment duration

 

 

<0.0001

≥ 3 cycles

13.7

11.7–15.7

 

< 3 cycles

2.8

1.2–4.4

 

TP53 mutations in evaluable patients

  • 50 TP53 mutations were sequenced in 39 patients
    • The vast majority were in the DNA-binding domain (92%)
    • 95% patients had at least one mutation in this domain
  • 51% of patients achieved TP53 negativity by next generation sequencing
    • In responders TP53 negativity reached significance after Cycle 3 (p < 0.0001)

Safety

  • Grade 3–4 adverse events (AEs) occurring in patients who were treated with APR-246 + AZA are shown in Table 3
  • Neurological toxicities were associated with lower glomerular filtration rate (p < 0.01) and older age (p = 0.01), and were manageable, reversible, and non-recurring following dose reduction
  • In total, 13 patients discontinued treatment prior to Cycle 3 analysis due to
    • severe infection (n = 6)
    • AML progression (n = 4)
    • multiorgan dysfunction (n = 2)
    • withdrawal of consent (n = 1)
  • One early discontinuation was secondary to an APR-246 adverse event
  • Patient mortality at 30 and 60 days were 0 and 8%, respectively

Table 3. Grade 3–4 AEs

Grade 3–4 AE

% of global cohort (N = 52)

Febrile neutropenia

37

Neurological

6

Ataxia

4

Acute confusion

2

AE, adverse event

Conclusions

Results from this trial indicate that the combination of APR-246 and AZA possesses encouraging safety and efficacy profiles in patients with TP53-mutated MDS and AML. The study highlighted subgroups of patients (elderly and those with renal failure) who may be particularly susceptible to neurologic side effects. Nonetheless, all AEs were manageable and reversible, and therefore close monitoring of these patients is recommended.

These data could contribute towards a more efficacious treatment route for patients with TP53 mutant disease whose options are currently limited.

  1. Cluzeau T, Sebert M, Rahmé R, et al. APR-246 combined with azacitidine in TP53 mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia. A phase 2 study by the Groupe Francophone des Myélodysplasies (GFM). Oral Abstract #S181. 25th EHA Annual Congress; Jun 12, 2020; Virtual.

Share: